A case–control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria by unknown
Jamil et al. Reproductive Health 2015, 12:7
http://www.reproductive-health-journal.com/content/12/1/7RESEARCH Open AccessA case–control observational study of insulin
resistance and metabolic syndrome among the
four phenotypes of polycystic ovary syndrome
based on Rotterdam criteria
Avin S Jamil1*, Shahla K Alalaf1, Namir G Al-Tawil2 and Talha Al-Shawaf3,4Abstract
Background: Polycystic ovary syndrome (PCOS) is associated with an increased risk of insulin resistance (IR), metabolic
syndrome (MetS), impaired glucose tolerance (IGT) and type 2 diabetes mellitus (T2DM). Metabolic aspects of the four
PCOS phenotypes remain to be fully defined. The aim of this study was to compare metabolic parameters and insulin
resistance among the four PCOS phenotypes defined according to the Rotterdam criteria and to determine predictors
of these complications.
Methods: A total of 526 reproductive-aged women were included in this observational case–control study. Of these,
263 were diagnosed as a PCOS based on Rotterdam criteria and 263 infertile women with no evidence of PCOS were
recruited as controls. Biochemical, metabolic and insulin resistance parameters were compared in the two groups and
the frequency of MetS and IR were compared among the four phenotypes. Data were analyzed for statistical significance
using Student’s t-test and one way analysis of variance followed by a post-hoc test (least significant difference).
Chi-square tests were used to compare proportions. Univariate and multivariate logistic regression analyses were
also applied.
Results: IR was identified in 112 (42.6%) of the PCOS women and 45 (17.1%) of the control (P <0.001). There were
no significant differences in the frequency of IR and MetS between the four PCOS phenotypes. Homeostatic model
assessment for IR (HOMA-IR) ≥3.8 was the most common IR parameter in PCOS and control groups. Women with
oligo-anovulation (O) and PCO morphology (P) had a significantly lower level of 2-h postprandial insulin compared to
women with O, P and hyperandrogenism (H) phenotypes.
Logistic regression analysis showed that body mass index, waist circumference, triglyceride/high-density lipoprotein
ratio (cardiovascular risk), HOMA-IR and glucose abnormalities (T2DM) were associated with increased risk of having
MetS (P < 0.05).
Conclusions: PCOS women with (O + P) show milder endocrine and metabolic abnormalities. Although, there were no
significant differences in IR, MetS and glucose intolerance between the four PCOS phenotypes, women with PCOS are
at higher risk of impaired glucose tolerance and undiagnosed diabetes.
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Polycystic ovary syndrome is one of the most common
endocrine disorders affecting women of reproductive age,
and is frequently but not consistently associated with insu-
lin resistance (IR) and compensatory hyperinsulinism (HI)
[1]. More than 50% of women with PCOS are insulin re-
sistant, with an estimated that they have a 5- to 8-fold in-
creased risk of type 2 diabetes mellitus (T2DM) compared
with age- and weight-matched controls [2,3]. The patho-
genesis of T2DM is critically affected by IR and B-cell dys-
function [4-6].
The prevalence of IR in PCOS patients ranges from 44
to 70% [7,8]. This wide range may be due to several factors,
including the heterogeneity of the diagnostic criteria for
PCOS employed in these studies [7], the genetic back-
ground among the assessed population [9] and differences
in the methods used for defining IR [7,10]. The presence
of chronic anovulation associated with higher androgen
levels correlates with lower insulin sensitivity and higher
prevalence of cardiovascular risk factors, such as IR, im-
paired glucose tolerance (IGT), T2DM, dyslipidemia and
metabolic syndrome (MetS). However, the presence of two
PCOS phenotypes identified according to the Rotterdam
criteria—hyperandrogenism and polycystic ovaries with
ovulatory cycles and anovulation and polycystic ovaries
without hyperandrogenism—show little or no evidence
of IR using surrogate markers [7].
It is still unclear whether milder phenotypes have the
same metabolic and reproductive consequences as the
more severe forms and therefore, whether all of these
metabolic complications should be considered using strict
screening procedures for those patients with milder phe-
notypes [11,12]. Some studies suggest that the additional
PCOS phenotypes introduced according to the 2003
Rotterdam criteria, particularly phenotype D (O + P),
are characterized by less severe endocrine and meta-
bolic abnormalities [12,13]. In contrast, one study re-
ported higher serum insulin levels in group B (O + H)
and an insignificant increase in homeostatic model as-
sessment of insulin resistance (HOMA-IR) scores among
groups B (O + H) and D (O + P) [14]; however, this dif-
ference was lost after matching for age and body mass
index (BMI) [15]. Thus, these observations suggest
that higher insulin levels and HOMA-IR scores exhibit
a stronger correlation with the higher prevalence of
obesity in these PCOS women than the phenotypes per
se [11,16].
To our knowledge, this is the first study to investi-
gate the prevalence of IR and MetS among the four
phenotypes of PCOS according to the Rotterdam cri-
teria in Erbil/Iraq. The aim of this study was to com-
pare the differences in clinical, metabolic and IR
parameters between PCOS, its four phenotypes and a
control group.Methods
Study subjects and design
This was a case–control observational study carried out
on 263 women confirmed to have PCOS based on Rotter-
dam criteria and 263 infertile women with no evidence of
PCOS as controls attending outpatient gynaecology and
fertility clinic in Maternity Teaching Hospital, which is the
only public maternity hospital in Erbil in the Kurdistan re-
gion of Iraq. Patients were recruited from 1st of April 2012
to 30th of June 2013. The study protocol was approved by
the Scientific and Ethical committee at the College of
Medicine, Hawler Medical University (Iraq). Informed con-
sent was obtained from all women included in the study.
The diagnosis of PCOS was based on the Rotterdam-
PCOS criteria [17]. According to these criteria, PCOS was
diagnosed if at least two of the following criteria were
present: oligomenorrhoea/anovulation (defined as delayed
menses >35 days or < 8 spontaneous hemorrhagic episodes/
year), clinical hyperandrogenism (hirsutism using modified
Ferriman–Gallwey score of ≥8) or biochemical hyperandro-
genism (total testosterone > 0.481 ng/ml) and polycystic
ovaries morphology on ultrasonography (12 or more
follicles in each ovary measuring 2–9 mm in diameter,
and/or increased ovarian volume >10 ml3).
Women with PCOS were divided into four phenotypes,
based on the presence of olig-anovulation (O), hyperan-
drogenism (H) and polycystic ovary morphology (P) : (i)
Phenotype A (O +H + P), (ii) Phenotype B (O+H), (iii)
Phenotype C (H + P) and (iv) Phenotype D (O + P).
The control group included 263 infertile women aged
18–39 year who attended the hospital during the period
of study for investigation of fertility or gynecological dis-
orders and who consented to participate in the study.
The women in the control group had regular menstrual
cycles (21-35 days), no evidence of hirsutism and no poly-
cystic ovary morphology on ultrasonography. They included
patients with male, tubal factor, unexplained infertility
or other non-endocrine or related conditions.
The following exclusion criteria were applied: the pres-
ence of systemic disease that could alter insulin sensitivity
(such as cardiovascular disease and diabetes mellitus);
women on medication for ≤6 months prior to the study
(including oral contraceptives, glucocorticoids, ovulation in-
duction agents, and estrogenic or anti-androgenic drugs or
any medication for dyslipidemia or anti-obesity drugs that
could alter the patient’s clinical presentation or hormonal
profile); women with other endocrinological abnormalities
such as primary hyperprolactinemia, thyroid dysfunction,
and Cushing syndrome, congenital adrenal hyperplasia and
androgen producing neoplasm.
Study protocol
Detailed histories (menstrual, fertility, hirsutism, acne, greasy
skin, acanthosis nigricance, scalp hair loss or thinning and
Jamil et al. Reproductive Health 2015, 12:7 Page 3 of 9
http://www.reproductive-health-journal.com/content/12/1/7family history of T2DM) were taken from all patients in-
cluded in the study. This was followed by a full examination
(including general and pelvic examinations).
Body weight (kg), height (cm), waist circumference (WC),
hip circumference (HC) and waist-to-hip ratio (WHR) were
measured in all women. The BMI was calculated by divid-
ing the weight (in kg) by the height (in m) squared to assess
obesity. Systolic blood pressure (SBP) and diastolic blood
pressure (DBP) were measured with a sphygmomanometer.
Blood samples for baseline measurements were collected
after an overnight fast on day 2 or day 3 of the menstrual
cycle in the control group and after a spontaneous bleeding
episode in the PCOS group or randomly in the case of
amenorrhea. The circulating levels of total testoster-
one, sex hormone binding globulin (SHBG) and insu-
lin (fasting and 2-h postprandial) were measured by
electro-chemiluminescence immunoassays (ELECYS 2010,
Modular Analytics E170, cobas e 601, Roche Diagnostics,
Mannheim, Germany). The intra- and inter-assay coeffi-
cients of variation for insulin were 0.7–1.5% and 2.4–4.9%,
respectively (μU/mL × 6.945 = pmol/L).
Anti-Müllerian hormone (AMH) was assayed using the
ultrasensitive an enzyme-linked immunosorbent assay
ELISA (AMH Gen II ELISA, Beckman Coulter, 250 S.
Kraemer Blvd, Brea, CA 92821 USA). Glucose, total choles-
terol (TC), high-density lipoprotein cholesterol (HDL-C),
low-density lipoprotein cholesterol (LDL-C) and triglycer-
ides (TG) were measured using an enzymatic colorimetric
method (BIOLABO REAGENTS SA 02160, Maizy, France).
On the same day as blood samples were collected, trans-
vaginal ultrasonography was performed with a 6.5 MHZ
frequency vaginal transducer (GE LOGIQ P3 Expert/Logic
P3, probe destination E8CS/E8C, USA) and the volume of
each ovary was determined, as well as the number of small
follicles in each ovary.
Immediately after baseline blood sampling, an oral
glucose tolerance test (OGTT) was performed in which
glucose (75 g) was administered orally and serum glucose
levels were determined at 0 and 120 min. A fasting plasma
glucose (FPG) of <100 mg/dL (5.6 mmol/L) and 2-h
glucose during OGTT <140 mg/dL (7.8 mmol/L) were
accepted as normal values [18].
Categories of increased risk for diabetes (prediabetes)
were defined as follows: impaired fasting glucose (IFG) was
diagnosed when FPG was between 100 and 125 mg/dL
(5.6–6.9 mmol/L) and IGT was diagnosed when the 2-h
plasma glucose (2-h PG) value during a 75 g OGTT was
between 140 and 199 mg/dL (7.8–11.0 mmol/L). Diabetes
mellitus was confirmed by FPG ≥126 mg/dL (7.0 mmol/L),
a 2-h PG value during a 75 g OGTT of ≥200 mg/dL
(11.1 mmol/L), or a random PG concentration ≥200 mg/dL
(11.1 mmol/L) in the presence of symptoms [18].
IR was diagnosed by the presence of one or more of
the following: fasting plasma insulin ≥20 μU/ml, fastingglucose/insulin ratio ≤4.5, 2-h glucose/ 2-h insulin ratio ≤1
and a cut-off value of HOMA-IR ≥3.8. HOMA was calcu-
lated using the formula = fasting glucose (mg/dL) × fasting
insulin (μU/mL)/405 [19].
The qualitative insulin sensitivity check index (QUICKI)
was calculated using the following formula [20]: 1/[log
fasting insulin (μU/mL) + log fasting glucose (mg/dL)].
Homeostatic model assessment was used to determine
B-cell function (HOMA-B) calculated according to the
formula [21]: (fasting insulin in μU/ml) × 20/ (fasting
glucose in mmol/L – 3.5) μU/ml/mmol/L.
The Matsuda insulin sensitivity index (ISI) was calcu-
lated using the formula [22]: 10,000/√(FG (mg/dL) × FI
(μU/mL) × G (mg/dL) × I (μU/mL) (FG, fasting plasma
glucose; FI, fasting plasma insulin; G, mean plasma glu-
cose concentration; and I, mean insulin concentration
during the OGTT).
MetS was defined according to American Heart Associ-
ation & National Heart, Lung and Blood Institute (AHA/
NHLBI, 2005) updated ATP-III Third report of the Na-
tional Cholesterol Education Program Adult Treatment
Panel III (NCEP ATP-III) (National Institute of Health
(NIH), 2007) guidelines [23], when three or more of the
following criteria were present: WC ≥88 cm, serum tri-
glycerides ≥150 mg/dL , high-density lipoprotein choles-
terol <50 mg/dL or the use of lipid lowering medication,
blood pressure (BP) ≥130/85 mmHg or the use of anti-
hypertensive medication, or FPG ≥100 mg/dL.
Statistical analysis
Data were analyzed using the Statistical Package for Social
Sciences (SPSS, version 19). The Student’s t- test was used
to compare means of two groups. One way analysis of
variance (ANOVA) was used to compare between means
of three or more groups. A post hoc test (least significance
difference (LSD); performed after ANOVA) was used to
determine the statistical significance of difference between
two groups. A chi square test of association was used to
compare between proportions. When more than 20% of
the expected counts were less than 5, Fisher’s exact test
was applied. Logistic regression analysis was used where
the dependent variable was a binary categorical variable.
Variables found (by univariate analysis) to be significantly
associated with the dependent variable were entered into
the regression model as independent variables. A P-value
of < 0.05 was considered to indicate statistical significant.
Results
A total of 590 women who visited the outpatient gynae-
cology and fertility clinic of the Maternity Teaching
Hospital, Erbil in the Kurdistan region of Iraq between
1st of April 2012 and 30th of June 2013 were eligible
for inclusion in this study; however, 17 PCOS patients
and 17 control individuals declined to participate and a
Table 1 The clinical, hormonal and metabolic parameters






Age (years) 26.78 ± 4.95 29.02 ± 6.04 <0.001
Waist (cm) 99.29 ± 13.30 93.25 ± 12.05 <0.001
Waist-hip ratio (WHR) 0.91 ± 0.75 0.89 ± 0.69 <0.001
BMI (kg/m2) 31.08 ± 5.82 28.66 ± 5.04 <0.001
Systolic blood pressure
(mmHg)
125.04 ± 11.94 123.25 ± 11.28 0.078
Diastolic blood pressure
(mmHg)
82.21 ± 8.07 81.29 ± 7.43 0.178
AMH (ng/mL) 5.39 ± 2.02 2.49 ± 1.72 <0.001
Total testosterone (ng/mL) 0.44 ± 0.21 0.27 ± 0.13 <0.001
SHBG (nmol/L) 28.01 ± 22.09 41.08 ± 32.39 <0.001
Glucose metabolism
profile
Fasting insulin (FI) (μU/ml) 15.98 ± 10.12 10.75 ± 5.62 <0.001
2-h insulin (2-h I) (μU/ml) 93.79 ± 69.33 59.15 ± 39.24 <0.001
Fasting glucose (FG) (mg/dL) 90.96 ± 16.72 90.01 ± 12.30 0.458
2-h glucose (2-h G)(mg/dL) 126.44 ± 46.75 116.06 ± 28.56 0.002
QUICKI 0.37 ± 0.03 0.34 ± 0.03 0.001
Ratio of 2-h glucose to 2-h
insulin
1.96 ± 1.35 2.58 ± 1.40 <0.001
Fasting glucose/fasting
insulin
7.74 ± 5.24 10.61 ± 5.88 <0.001
HOMA-IR 3.67 ± 2.683 2.41 ± 1.42 <0.001
HOMA-B 227.99 ± 154.67 161.94 ± 105.27 <0.001
Matusda index 5.21 ± 3.75 7.19 ± 4.13 0.005
Insulin resistance (IR) 112 (42.6) 45 (17.1) <0.001
Normal GTT 176 (66.9) 196 (74.5) 0.105
Prediabetes (IFG and/or IGT) 75 (28.5) 61 (23.2)
Type 2 diabetes mellitus 12 (4.6) 6 (2.3)




173.30 ± 34.86 165.29 ± 32.59 0.018
Triglycerides (TG) (mg/dL) 125.73 ± 87.01 96.73 ± 57.15 <0.001
HDL (mg/dL) 43.69 ± 9.68 45.22 ± 8.85 0.059
LDL (mg/dL) 81.55 ± 23.83 77.31 ± 21.87 0.034
Cardiovascular risk (TG/HDL) 3.17 ± 3.03 2.28 ± 1.61 <0.001
Metabolic syndrome (MetS) 141 (53.6) 86 (32.7) <0.001
Values are presented as mean ± standard deviation or number (%). P-values
were calculated using Student’s t- test and Chi-square test.
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endocrinological abnormalities.
Table 1 depicts the clinical and biochemical characteris-
tics of the PCOS and control groups. Glucose metabolism
profiles were significantly different between the groups
(P < 0.05); the PCOS group had higher values for fasting
insulin, 2-h glucose, 2-h insulin, QUICKI, HOMA-IR,
fasting glucose/fasting insulin, HOMA-B, Matusda index,
ratio of 2-h glucose to 2-h insulin, IR, and MetS than
those for the control group. Lipid profiles also differed sig-
nificantly between the two groups; the PCOS group had
higher triglyceride, total cholesterol, low-density lipopro-
tein (LDL) levels and cardiovascular risk (TG/HDL) than
the control group as shown in Table 1. The PCOS group
was associated with a greater risk (2.5-times) of IR than
the control group (P < 0.001).
Table 2 shows that the fasting serum triglycerides, HDL,
TG/HDL, glucose, 2-h glucose and HOMA-IR were simi-
lar in the four PCOS phenotypes; however, significantly
higher levels of fasting insulin, 2-h insulin and HOMA-IR,
lower glucose/insulin ratio (GIR) and QUICKI were
observed in the four PCOS phenotypes compared with
the controls (P < 0.001). Women with phenotype D PCOS
had significantly lower 2-h insulin levels compared with
women with PCOS phenotype A (P < 0.001) (Table 2).
Women with PCOS phenotype C presented with the
same characteristics as those with classic PCOS (phenotype
A), but in a milder form; this may represent a transition
between the classic form and the control group.
After multiple comparisons and post-hoc analysis, women
with PCOS phenotype D were found to demonstrate milder
endocrine and metabolic abnormalities than those of
women with the other phenotypes.
The Matsuda (insulin sensitivity) Index was significantly
higher in the control group compared with the PCOS
phenotype A and D groups.
Table 3 describes the elements that contribute to IR. All
of the parameters that made up that contribute to IR were
significantly greater in women with PCOS and in various
phenotypes than in the controls (P < 0.001). Among the
PCOS, PCOS phenotypes and control groups, similar re-
sults were obtained for glucose tolerance tests (P = 0.092)
(Table 3).
A higher proportion of women in the PCOS group pre-
sented with T2DM compared with that in the control
group (4.6 vs 2.3%, respectively). This higher rate of T2DM
was present predominantly in the phenotype D (6.4%),
although the numbers were small to assess the statistical
significance of this observation. The prevalence of predia-
betes (IFG and/or IGT) was similar to that of T2DM be-
tween the groups.
There were no significant differences in the rates IR
and MetS among the women with the different PCOS
phenotypes; however, the lowest rate of IR was observedin the phenotype D, with this rate being approximately
33% lower than those in other PCOS phenotype groups.
Furthermore, the highest rates of IR and MetS were ob-
served in the PCOS phenotype B group.
Multivariable logistic regression analysis showed that
BMI, WC, TG/HDL (CV risk), HOMA-IR and glucose












Age (years) 26.96 ± 4.67b,e 32.70 ± 2.71a,c,d,e 26.64 ± 4.86e 25.76 ± 5.19e 29.02 ± 6.03a,b,c,d <0.001
Waist (cm) 100.85 ± 12.42d,e 103.50 ± 8.71e 96.86 ± 14.08 97.10 ± 14.5e 93.25 ± 12.05a,b,d <0.001
Waist/hip ratio 0.92 ± 0.06e 0.95 ± .05e 0.91 ± 0.09 0.91 ± 0.08 0.89 ± 0.07 a,b 0.001
BMI (kg/m2) 31.79 ± 5.79c,e 32.83 ± 4.83e 29.41 ± 5.67a 30.36 ± 5.88e 28.66 ± 5.04a,b,d <0.001
Systolic blood pressure (mmHg) 126.37 ± 12.46d,e 129.50 ± 13.01 122.78 ± 10.92 123.14 ± 10.99a 123.25 ± 11.28a 0.043
Diastolic blood pressure (mmHg) 82.81 ± 8.82 84.50 ± 4.97 80.42 ± 8.31 81.67 ± 6.67 81.29 ± 7.42 0.214
Cholesterol (mg/dL) 176.70 ± 31.66c,e 177.40 ± 31.39 162.44 ± 27.11a 168.35 ± 42.30 165.29 ± 32.59e 0.015
Triglycerides (mg/dL) 130.37 ± 90.88e 144.50 ± 45.32e 105.61 ± 59.51 124.33 ± 93.93e 96.73 ± 57.15 a,b,d <0.001
HDL(mg/dL) 43.74 ± 9.70 42.78 ± 8.12 43.99 ± 9.96 43.59 ± 9.86 45.22 ± 8.84 0.450
LDL (mg/dL) 85.08 ± 24.79c,d,e 83.70 ± 20.90 74.05 ± 17.21a 78.44 ± 24.19a 77.31 ± 21.87a 0.010
TG/HDL (CV risk)* 3.31 ± 3.45e 3.44 ± 1.15 2.69 ± 1.95 3.12 ± 2.807e 2.28 ± 1.6a,d 0.001
Fasting glucose (FG) 91.29 ± 19.74 93.70 ± 16.02 87.58 ± 10.1 91.58 ± 13.04 90.01 ± 12.3 0.555
2-h glucose 129.45 ± 49.9e 128.90 ± 30.76 124.36 ± 53.95 121.73 ± 38.49e 116.06 ± 28.52a,d 0.022
Fasting insulin (FI) 16.86 ± 11.41e 18.52 ± 11.18e 14.51 ± 7.65e 14.76 ± 8.22 e 10.74 ± 5.61a,b,c,d <0.001
2-h insulin 103.63 ± 74.65d,e 101.91 ± 81.45e 93.60 ± 69.4e 75.29 ± 53.01a,e 59.15 ± 39.2a,b,c,d <0.001
Fasting glucose/fasting insulin 7.30 ± 4.40e 7.21 ± 4.78e 8.14 ± 4.87e 8.46 ± 6.64e 10.64 ± 5.89a,b,c,d <0.001
Ratio of 2-h glucose to 2-h insulin 1.86 ± 1.40e 1.56 ± 0.84e 2.04 ± 1.66e 2.15 ± 1.17e 2.58 ± 1.40a,b,c,d 0.001
Matsuda index 4.81 ± 3.449e 5.01 ± 4.19 6.02 ± 5.33 5.58 ± 3.28e 7.19 ± 4.13a,d 0.001
HOMA-IR 3.873 ± 2.99e 4.48 ± 3.27e 3.19 ± 1.86e 3.46 ± 2.29e 2.41 ± 1.42a,b,c,d <0.001
HOMA-B 237.14 ± 163.32e 245.35 ± 139.7 227.93 ± 162.2e 210.21 ± 138.2e 161.93 ± 105.27a,c,d 0.001
QUICKI 0.32 ± 0.02e 0.32 ± 0.03e 0.33 ± 0.03e 0.32 ± 0.03e 0.34 ± 0.02a,b,c,d <0.001
Values are presented as mean ± standard deviation. P-values were calculated using one-way ANOVA followed by multiple comparisons (post hoc test (least
significance difference (LSD)).
*(TG/HDL) Triglyceride/ high-density lipoprotein (fasting), CV: cardiovascular risk.
aP < 0.05 versus phenotype A PCOS, bP < 0.05 versus phenotype B PCOS, cP < 0.05 versus phenotype C PCOS, dP < 0.05 versus phenotype D PCOS, eP < 0.05 versus control.
(Note: (i) Phenotype A (O + H + P), (ii) Phenotype B (O + H), (iii) Phenotype C (H + P) and (iv) Phenotype D (O + P). A: Oligo-anovulation (O), + Hyperandrogenism
(H), + Polycystic ovaries morphology (P).
Jamil et al. Reproductive Health 2015, 12:7 Page 5 of 9
http://www.reproductive-health-journal.com/content/12/1/7abnormalities (T2DM) were associated with an increased
risk of MetS (P < 0.05) (Table 4).
In logistic regression analysis using IR as a dependent
variable, phenotype A (OR = 4.13; 95% CI for OR 2.602–
6.567), B (OR = 4.84; 95% CI for OR 1.35–17.43) and C
(OR = 4.33; 95% CI for OR 2.1–8.98) was shown to be
associated with a four-fold increased risk of developing
IR, while phenotype D (OR = 2.42; 95% CI for OR 1.37–
4.28) was associated with only a two-fold increased risk
in comparison to the control group (Table 5).
Among the groups studied, PCOS phenotype A [OR =
2.874 (1.880–4.393 95%CI) and B OR = 8.233 (1.711–
39.601 95%CI)] showed a highly positive association with
MetS in comparison to control in logistic regression ana-
lysis (P < 0.001) (Table 6).
Discussion
The Rotterdam criteria for women with PCOS resulted in
four phenotypes, which have dissimilar risks for IR and
MetS. PCOS phenotypes with hyperandrogenism (A, B
and C) have the worst metabolic presentations in terms ofIR and MetS. Our findings also indicate that concurrency
of these three PCOS phenotypes leads to increased sever-
ity of metabolic disorders, especially hyperinsulinemia,
which may be related to more severe hyperandrogenemia
(HA). All of the PCOS women in this study had higher tri-
glyceride, total cholesterol, low-density lipoprotein (LDL),
fasting insulin levels and HOMA-IR than the controls
(which is consistent with previous reports [24]), and 2-h
postprandial insulin [25].
Similar to our findings, a study conducted on 93 Polish
women with PCOS, showed elevated serum concentra-
tions of total cholesterol and LDL in the phenotype A
PCOS compared with those with phenotypes C and D
[14,26].
In our study, phenotype B (O + H) PCOS showed the
highest prevalence of MetS among the four PCOS pheno-
types; these women were older and also had higher WHR,
indicating a higher incidence of androgenic obesity and
this higher prevalence is very likely to be related to higher
BMI. These observations are in accordance with those
reported by Tahrani et al. [26] and Welt et al. [27]. Women
















Fasting insulin ≥20 μU/mL 64 (24.3) 33 (23.7) 4 (40) 10 (27.8) 17(21.8) 17 (6.5) <0.001
Fasting glucose/Fasting insulin ≤4.5 61 (23.2) 32 (23) 4 (40) 10 (27.8) 15(19.2) 17 (6.5) < 0.001
HOMA-IR≥ 3.8 90 (34.2) 49 (35.3) 5 (50) 12 (33.3) 24(30.8) 36 (13.7) < 0.001
Ratio 2-h glucose/2-h insulin ≤1 61 (23.2) 40 (28.8) 3 (30) 9 (25) 9 (11.5) 13(4.9) < 0.001
Normal GTT 176 (66.9) 88 (63.3) 5 (50) 26 (72.2) 57(73.1) 196(74.5) 0.092
Prediabetes (IFG and/or IGT) 75 (28.5) 46 (33.1) 5 (50) 8 (22.2) 16(20.5) 61(23.2)
Type 2 diabetes mellitus 12 (4.6) 5 (3.6) 0 (0) 2 (5.6) 5 (6.4) 6 (2.3)
Insulin resistance (IR) 112 (42.6) 64 (46)* 5 (50)* 17(47.2)* 26(33.3)* 45(17.1) <0.001
Metabolic syndrome (MetS) 141 (53.6) 81 (58.3)** 8(80)** 17(47.2)** 35(44.9)** 86(32.7) <0.001
Family history of T2DM 131 (49.8) 65 (46.8)+ 4 (40)+ 18 (50)+ 44(56.4)+ 104 (39.5) 0.094
Data are shown as n (%). P-values were calculated using Chi-square test.
*Insulin resistance frequencies did not differ significantly between the PCOS phenotypes (P = 0.271).
**Metabolic syndrome frequencies did not differ significantly between phenotypes (P = 0.069).
+Family history of T2DM frequencies did not differ significantly between phenotypes (P = 0.525).
(Note: (i) Phenotype A (O + H + P), (ii) Phenotype B (O + H), (iii) Phenotype C (H + P) and (iv) Phenotype D (O + P). IFG: impaired fasting glucose, IGT: impaired
glucose tolerance.
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MetS compared with those with phenotype C and the
controls [28]. A comparison of PCOS patients diagnosed
according to the Rotterdam, the Androgen Excess Society
(AES) and the National Institute of Health (NIH) criteria
conducted by Amato et al. [29] revealed that, regardless of
the diagnostic criteria used, metabolic parameters and
insulin sensitivity are critically important for the correct
diagnosis and treatment of PCOS.
The prevalence of IR is higher among PCOS patients
than that among control women (42.6 vs 17.1%); therefore,
we further compared the hyperandrogenic and non-Table 4 Logistic regression of metabolic syndrome as a
dependent variable
Independent variable B P-value OR 95% CI for OR
Lower Upper
AMH 0.063 0.290 1.065 0.948 1.198
BMI 0.140 0.002 1.150 1.053 1.257
Waist circumference 0.066 0.001 1.068 1.028 1.110
TG/HDL (CV risk) 1.008 <0.001 2.739 2.170 3.458
HOMA-IR 1.414 0.001 4.114 1.823 9.282
Fasting insulin −0.300 0.002 0.741 0.612 .896
2-h insulin −0.004 0.134 0.996 0.990 1.001
Total testosterone −0.765 0.303 0.465 0.108 1.997
Glucose abnormalities 0.024
Impaired GTT 0.603 0.080 1.827 0.930 3.592





Constant −13.579 < 0.001 0.000
OR: odd ratio; CI: confidence interval.hyperandrogenic phenotypes of PCOS women in rela-
tion to IR and MetS. There were no significant differences
in the prevalence of IR between the four phenotype groups
[A (O +H + P) (46%), phenotype B (O +H) (50%), pheno-
type C (H + P) (47.2%) and phenotype D (O + P) (33.3%)].
Similarly, Kauffman et al. showed that insulin sensitivity
indices were comparable across all PCOS phenotypes [30].
The many possible reasons for these inconsistencies in-
clude genetic variation between ethnic populations, envir-
onmental factors (including obesity) and the heterogeneity
of PCOS phenotypes.
A comparison of markers of IR and endocrine character-
istics between the different PCOS phenotypes conducted
by Panidis et al. revealed that phenotype A (O +H+ P) was
associated with a higher prevalence of IR and more pro-
nounced hyperandrogenemia than phenotype B (H +O).
Phenotypes B (H + O) and D (O + P) with concurrentTable 5 Logistic regression of insulin resistance as
dependant variable and phenotype-control as independent
variable
Variables B P OR 95% C.I. for OR
Lower Upper
Phenotype-control < 0.001
A 1.419 < 0.001 4.134 2.602 6.567
B 1.578 0.016 4.844 1.346 17.432
C 1.467 < 0.001 4.335 2.091 8.984
D 0.885 0.002 2.422 1.370 4.282
Control (reference) 1.000
Constant −1.578 < 0.001 0.206
Table 6 Logistic regression analysis for metabolic
syndrome as dependant variable
Variables B P OR 95% C.I. for OR
Lower Upper
Phenotype-control <0.001
A 1.056 <0.001 2.874 1.880 4.393
B 2.108 0.009 8.233 1.711 39.601
C 0.611 0.089 1.841 0.912 3.720
D 0.516 0.050 1.675 1.001 2.804
Control (reference) 1.000
Constant −0.722 <0.001 0.486
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type C (H + P) was not associated with IR [11].
In accordance with our findings, Goverde et al. observed
that the prevalence of metabolic disturbances and IR var-
ies between different anovulatory PCOS phenotypes and
reported that anovulatory hyperandrogenic women with
phenotype A and B (with or without polycystic ovaries)
had a higher prevalence of IR compared with phenotype D
PCOS women and showed that WC was a predictor of
MetS [31]. As another indicator of IR, our study adds that
serum SHBG levels were significantly lower in all four
PCOS phenotypes compared with those in the control
group, which is consistent with previous reports [32,27,33].
Furthermore, both phenotypes A and B were more insulin
resistant (greater prevalence) than the control, which has
also been reported previously [33-35].
In some previous studies, no differences in fasting
blood glucose levels were identified between the PCOS
phenotypes and the control groups [27,36], while another
study showed higher blood glucose levels in H + O and
H + P patients compared with control subjects [34]. Our
data did not reveal any differences in serum glucose levels
according to the 75 g GTT among the four PCOS pheno-
type, which is consistent with previous report [30].
In our study, although there were no significant differ-
ences in fasting insulin levels among the PCOS pheno-
types, there were significant differences between the PCOS
phenotypes and the control group. The present study also
showed that 2-h postprandial serum insulin levels were sig-
nificantly higher in the phenotype A than in the phenotype
D PCOS, which is in agreement with the results reported
by Chae et al. [37]. This may suggest that postprandial
hyperinsulinemia plays an important role in HA and ovar-
ian function in Iraqi women with PCOS.
As the glucose–insulin ratio decreases, the degree of
IR increases. Shroff et al. reported the highest glucose–
insulin ratio in the control group and the lowest ratio
in the P + H +O phenotype group [34]. In our study,
the lowest glucose–insulin ratio values were in the P +
H +O and H +O phenotype groups, while the highestvalues were detected in the O + P phenotype and control
groups, which is in accordance with the findings of
Yilmaz et al. [24].
In a study comparing HOMA-IR scores, the highest
values were detected in the P + H +O and H +O pheno-
types and the lowest values were detected in the H + P
phenotype and control groups [27], which is consistent
with our findings. In another study, the highest HOMA-
IR scores were associated with the H + P phenotype and
the lowest with the O + P phenotype [34]. Chae et al. re-
ported that there were no differences in HOMA-IR scores
among the PCOS phenotypes, although there were sig-
nificant differences between PCOS phenotypes and the
control group, which is also in accordance with our re-
sults [37].
An increased risk of prediabetes (IFG and/or IGT) and
T2DM in women with PCOS has been reported previ-
ously [38]. The present study showed a trend toward a
higher risk of prediabetes (IFG and/or IGT) and T2DM
associated with all PCOS phenotypes, compared with con-
trol subjects. These observations indicate the potential
benefit of performing a 75 g 2-h OGTT in confirming
glucose intolerance to inform the clinical prognosis and
management of PCOS patients. The higher rate of T2DM
in phenotype D PCOS may be related to the genetic factors
because of higher percentage of family history of T2DM in
this phenotype [39].
Using different surrogate markers of IR, we were unable
to detect any significant differences in the prevalence of IR
among the four PCOS phenotypes. Although we did
not measure insulin sensitivity directly, a significant cor-
relation between HOMA-IR and the insulin sensitivity
index (gold standard euglycemic hyperinsulinemic clamp
methods) has been identified in women with PCOS [40].
Logistic regression analysis revealed only a 2-fold in-
creased risk of IR in phenotype D, while phenotype C
had a 4-fold increased risk; these findings are similar to
those reported by Svendsen et al. [41] who found that
women diagnosed with phenotype C PCOS showed a
higher degree of IR compared with those with pheno-
type D.
The numbers in group B (O +H) PCOS were small to
assess the statistical significance and it’s regarded as the
limitation of the study.
Conclusion
In conclusion, our study conducted in a representative
sample of the PCOS population, indicates that there is
no significant difference in the prevalence of IR and MetS
between the PCOS phenotypes, although there are sig-
nificant differences between women with PCOS and non
PCOS (control). Specifically, the prevalence IGT and
undiagnosed diabetes is higher among women with
PCOS. Women with phenotypes A and B exhibit the
Jamil et al. Reproductive Health 2015, 12:7 Page 8 of 9
http://www.reproductive-health-journal.com/content/12/1/7worst metabolic features. WC represents a clinically useful
parameter for identifying anovulatory women with PCOS
who should be screened for the presence of MetS.
PCOS women without HA showed lower 2-h postpran-
dial insulin levels than PCOS subjects with HA. PCOS
without HA could simply be a milder phenotype of PCOS,
and may be associated with fewer metabolic complications.
MetS is positively correlated with BMI, WC, TG/HDL
(CV risk), HOMA-IR and glucose abnormalities (T2DM).
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